Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.773.875 G07.690.936.500
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 5 | 5 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 8 | 8 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 6 | 6 |
| 2007 | 0 | 8 | 8 |
| 2008 | 0 | 13 | 13 |
| 2009 | 0 | 9 | 9 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 8 | 8 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 3 | 3 |
| 2016 | 1 | 3 | 4 |
| 2017 | 0 | 5 | 5 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025 Dec 06; 406(10520):2631-2643.
-
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Sep 18; 393(11):1065-1076.
-
Effect of Perinatal Vitamin D Deficiency on Lung Mesenchymal Stem Cell Differentiation and Injury Repair Potential. Am J Respir Cell Mol Biol. 2021 11; 65(5):521-531.
-
Amiodarone: A Comprehensive Guide for Clinicians. Am J Cardiovasc Drugs. 2020 Dec; 20(6):549-558.
-
Arctigenin inhibits prostate tumor growth in high-fat diet fed mice through dual actions on adipose tissue and tumor. Sci Rep. 2020 Jan 29; 10(1):1403.
-
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019 11; 290:59-65.
-
Vancomycin-Associated Acute Kidney Injury in a Large Veteran Population. Am J Nephrol. 2019; 49(2):133-142.
-
Low-Dose and Standard Overnight and Low Dose-Two Day Dexamethasone Suppression Tests in Patients with Mild and/or Episodic Hypercortisolism. Horm Metab Res. 2018 Jun; 50(6):453-461.
-
Difluprednate for the Treatment of Uveitic Cystoid Macular Edema. Am J Ophthalmol. 2018 07; 191:14-22.
-
Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial. J Intern Med. 2018 03; 283(3):314-327.